Pfizer Inc. Reviewing Possible Divestitures, Executives Says; R&D Chief Aims to Complete Review This Year

(Reuters) - Pfizer Inc (PFE.N) plans to complete a review this year of whether it should divest any of its businesses to maximize their value, a top executive at the drugmaker said on Thursday.

MORE ON THIS TOPIC